Laura Modi, co-founder and CEO of infant formula startup Bobbie, is on a mission to transform an industry that she says has been stagnant for decades, and shift the culture around how parents feed their babies.Modi, a former Airbnb executive, came up with the idea for Bobbie after the birth of her first child."I remember walking into a pharmacy buying infant formula and hoping that they would give me a bag that you couldn't see through it, because I felt so embarrassed about the product that I was buying," ...

Summary of Mengniu Dairy (2319.HK) 1H25 Results and Key Insights Company Overview - **Company**: Mengniu Dairy - **Ticker**: 2319.HK - **Reporting Period**: 1H25 - **Report Date**: August 27, 2025 Key Financial Highlights 1. **Sales and Net Profit**: - Total sales decreased by **6.9% year-on-year (yoy)** to **Rmb 41.6 billion** - Net profit fell by **16.4% yoy** to **Rmb 2.0 billion** [1][9] 2. **Core Operating Profit (OP)**: - Core OP increased by **13% yoy**, with an Operating Profit Margin (OPM) of **8.5%**, up **150 basis points (bps)** yoy, exceeding the market expectation of **7.6%** [1][8] 3. **Gross Profit Margin (GPM)**: - GPM expanded by **1.5 percentage points (pp)** in 1H25, attributed to lower raw milk costs [1][8] 4. **Cash Flow**: - Operating Cash Flow (OCF) improved to **Rmb 2.8 billion**, a **46% increase** from **Rmb 1.92 billion** in June 2024 [1][8] 5. **Capital Expenditure (Capex)**: - Capex significantly reduced by **40% yoy** to **Rmb 1.0 billion** in 1H25 [1][8] 6. **Net Debt**: - Net debt decreased by **19% half-on-half (HoH)** to **Rmb 14.1 billion** from **Rmb 17.3 billion** at the end of 2024 [1][8] Segment Performance 1. **Liquid Milk Sales**: - Liquid milk sales declined by **11% yoy**, below market expectations by **5%** [1][7] - Fresh milk and low-temperature yogurt showed growth, while ice cream sales increased by **15% yoy** [1][7] 2. **Other Dairy Products**: - Infant formula sales grew by **2% yoy**, and other dairy products (including cheese) increased by **12% yoy** [1][7] Challenges and Risks 1. **Associate Losses**: - Higher associate losses due to raw milk price cycles, with losses of **Rmb 545 million** in 1H25 compared to **Rmb 133 million** in 1H24 [1][9] 2. **Interest Income**: - Interest income decreased to **Rmb 540 million** from **Rmb 914 million** [1][9] 3. **Tax Rate**: - Effective tax rate increased to **24%**, primarily due to associate losses, compared to **18%** in 1H24 [1][9] Future Outlook 1. **Demand Outlook**: - Upcoming onsite briefing scheduled for August 28, focusing on demand outlook for liquid milk, growth expectations for 2H25, and product plans [1][3] 2. **Raw Milk Cycle**: - Industry herd size is declining, with expectations for further reductions, impacting raw milk supply and pricing [1][10] 3. **Shareholder Returns**: - Discussion on shareholder return plans is anticipated in the upcoming briefing [1][3] Management Changes - **CFO Appointment**: Mr. Shen Xinwen appointed as CFO effective September 1, 2025, succeeding Mr. Zhang Ping [2][2] Investment Considerations - **Price Target**: Goldman Sachs maintains a **Buy** rating with a 12-month price target of **HK$ 23.30**, representing an upside of **43.8%** from the current price of **HK$ 16.20** [13][14] - **Risks**: Key risks include slower-than-expected premium demand, intense competition, and potential wider losses in new categories [13][13]

Core Insights - Perrigo (PRGO) reported adjusted earnings of 57 cents per share for Q2 2025, missing the Zacks Consensus Estimate of 59 cents, but showing a year-over-year increase of 7.5% primarily due to lower interest expenses [1][7] - Net sales decreased by 0.9% year-over-year to $1.06 billion, falling short of the Zacks Consensus Estimate of $1.08 billion, attributed to lost sales from exited businesses and product lines, although partially offset by favorable currency movements [1][2] Sales Performance - Sales dropped 2.5% year-over-year due to exited businesses and product lines, but were positively impacted by a 1.7% favorable currency effect; at constant currency, sales fell 2.6% [2] - Organic net sales declined by 0.1%, indicating a slight decrease when excluding acquisitions, divestitures, and currency impacts [2] Segment Analysis - Consumer Self Care Americas (CSCA) reported net sales of $622 million, down 1.9% year-over-year, with growth in Nutrition, Healthy Lifestyle, and Upper Respiratory categories offset by declines in Digestive Health and Oral Care; organic net sales also fell by 1.9% [4] - Consumer Self Care International (CSCI) reported net sales of $434 million, up 0.7% year-over-year, driven by favorable currency translation and organic sales growth, although at constant currency, sales decreased by 3.5%; organic sales increased by 2.7% [5] Financial Guidance - Perrigo lowered its financial guidance for total sales in 2025, now expecting growth towards the lower end of the previously issued range of 0-3%, primarily due to challenges in the infant formula industry and market consumption trends [6][10] - Despite the downward revision in sales, the company maintained its adjusted EPS guidance of $2.90-$3.10, with an adjusted gross margin around 40% and an adjusted operating margin near 15% [10] Market Reaction - Following the guidance revision, Perrigo's stock price declined by 6% during pre-market trading [6]

Financial Performance - Net sales reached $1056 million, a decrease of 0.9% year-over-year[16] - Organic net sales experienced a slight decrease of 0.1% year-over-year[16] - Adjusted gross profit was $403 million, down 6.9% year-over-year[16] - Adjusted gross margin was 38.1%, a decrease of 250 basis points[16] - Adjusted operating income was $1352 million, down 2.9% year-over-year[16] - Adjusted EPS increased by 7.5% to $057[16] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 1.9% year-over-year to $622 million[43] - Consumer Self-Care International (CSCI) net sales increased by 0.7% year-over-year to $4343 million[43] - Perrigo OTC brands grew by 3.6%, while Perrigo OTC store brands decreased by 3.2%[19] Strategic Initiatives - Infant formula net sales increased by 9% year-over-year[14] - Store brand and contract infant formula net sales increased by 32% year-over-year[26] - Project Energize is expected to deliver $159 million in annual run rate gross savings[30] - Supply Chain Reinvention is expected to generate total benefits between $150-$200 million by the end of 2025[30] - The sale of the Dermacosmetics business is expected to close in Q1 2026, with proceeds prioritized for accelerating net leverage goals[30, 52]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Abbott, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - Abbott is expected to report quarterly earnings of $1.25 per share, reflecting a +9.7% change year-over-year, with revenues projected at $11.07 billion, up 6.7% from the previous year [3]. - The earnings report is scheduled for July 17, and better-than-expected results could lead to a stock price increase, while a miss may result in a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.44% lower in the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP of +0.96% suggests analysts have recently become more optimistic about Abbott's earnings prospects, combined with a Zacks Rank of 2 indicating a likely earnings beat [12]. Earnings Surprise History - Abbott has a history of beating consensus EPS estimates, having exceeded expectations in three out of the last four quarters [14]. - In the last reported quarter, Abbott's earnings of $1.09 per share surpassed the expected $1.07, resulting in a surprise of +1.87% [13]. Conclusion - Abbott is positioned as a strong candidate for an earnings beat, but investors should consider additional factors beyond earnings results when making investment decisions [15][17].

Core Viewpoint - Abbott (ABT) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to buying or selling actions that affect stock prices [4]. Abbott's Earnings Outlook - For the fiscal year ending December 2025, Abbott is expected to earn $5.16 per share, with a 0.2% increase in the Zacks Consensus Estimate over the past three months [8]. - The upgrade reflects an improvement in Abbott's underlying business, which is likely to drive the stock price higher as investor sentiment improves [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - Stocks rated Zacks Rank 1 have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the system [7].